Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 94, Issue 1, Pages 80-94Publisher
WILEY
DOI: 10.1038/clpt.2013.34
Keywords
-
Categories
Ask authors/readers for more resources
Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theoretical possibility of adverse central nervous system (CNS) effects identified in preclinical studies. In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available